2. Academic Validation
  3. Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development

Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development

  • J Med Chem. 2009 Dec 10;52(23):7360-3. doi: 10.1021/jm900786r.
Mark D Wittman 1,  Joan M Carboni,  Zheng Yang,  Francis Y Lee,  Melissa Antman,  Ricardo Attar,  Praveen Balimane,  Chiehying Chang,  Cliff Chen,  Lorell Discenza,  David Frennesson,  Marco M Gottardis,  Ann Greer,  Warren Hurlburt,  Walter Johnson,  David R Langley,  Aixin Li,  Jianqing Li,  Peiying Liu,  Harold Mastalerz,  Arvind Mathur,  Krista Menard,  Karishma Patel,  John Sack,  Xiaopeng Sang,  Mark Saulnier,  Daniel Smith,  Kevin Stefanski,  George Trainor,  Upender Velaparthi,  Guifen Zhang,  Kurt Zimmermann,  Dolatrai M Vyas
Affiliations

Affiliation

  • 1 Bristol-Myers Squibb Co, Wallingford, Connecticut 06492, USA.
PMID: 19778024 DOI: 10.1021/jm900786r
Abstract

This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development.

Figures
Products